Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia

Completed · Phase 4

Conditions studied: Focal Dystonia

In brief

This study uses a computerized method of musical instrument digital interface (MIDI) quantification of performance before and after treatment with botulinum toxin type B (Myobloc ®, Solstice Neurosciences). Myobloc is a purified and diluted form of botulinum toxin used medically to relax unwanted muscle spasms and movements. The aim of the study is to determine the feasibility of quantifying change in performance following treatment.

Key facts

Study ID

NCT00208091

Run by

Columbia University

People needed

16

Starts

2003-04-01

Expected to finish

2008-05-01

Last updated by the study team

2014-05-09

Who can join

Age: 25 and older, up to 69. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Focal, task-specific dystonia clinically determined to be the result of a high level of musical skill and intensive performance history

You may not qualify if…

• Neurological disorders other than dystonia
• Patients who are clinically depressed, demented or otherwise unable to perform appropriately or sit through 1 hour of testing
• Patients who have undergone pallidotomy, thalamotomy or deep brain stimulator implantations
• Patients who have who recently have taken medications with extrapyramidal or tremorogenic side effects

Where it is running

• Neurological Institute, 710 W. 168th Street, NI-1112 — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.